<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767585</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OSI-DUM-2008/1</org_study_id>
    <nct_id>NCT00767585</nct_id>
  </id_info>
  <brief_title>An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice</brief_title>
  <official_title>An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effect of aromatase inhibitors therapy on bone
      mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of aromatase inhibitors therapy on bone mineral density as measured by DEXA scan and compare it to the effects of tamoxifen and no hormonal therapy.</measure>
    <time_frame>once</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the bone fracture rate in women on aromatase inhibitors therapy and compare it to fracture rates observed in the tamoxifen and the hormone-independent group.</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>A:</arm_group_label>
    <description>70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <description>70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <description>70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <description>70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <description>70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <description>70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Institute of Oncology
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 55-65 years, diagnosed with invasive early breast cancer: - Surgery, chemo-
             and/or radiotherapy concluded less than 6 months ago

          -  Women with hormone-independent breast cancer: - Surgery, chemo- and/or radiotherapy
             concluded before 24-36 months or 54-66 months

          -  Women with hormone-dependent breast cancer:- Adjuvant therapy with tamoxifen initiated
             before 24-36 and 54-66 months or - Adjuvant therapy with aromatase inhibitor initiated
             before 24-36 and 54-66 months or - Switch from tamoxifen to aromatase inhibitor
             initiated before 24-36 months

        Exclusion Criteria:

          -  Women receiving active treatment for osteoporosis

          -  Women with any evidence of breast cancer recurrence
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simona Borstnar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Oncology Ljubljana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>July 2, 2009</last_update_submitted>
  <last_update_submitted_qc>July 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Meta Jeras, Mr Ph, Regulatory and Medical Affairs Manager</name_title>
    <organization>AstraZeneca UK Limited, Branch Office in Slovenia</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

